Categories Earnings, Health Care

Earnings: Trevena slips on wider-than-expected Q4 loss

Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market trading. Helped by substantially lower research and development expenses during the quarter, net loss narrowed to 10 cents per share from 24 cents per share a year ago.

However, this wasn’t good enough for the street, which was expecting a loss of only 6 cents per share.

Image for representation (Image Courtesy: Louis Reed/Unsplash)

Q4 revenue of the clinical-stage biopharmaceutical company stood at $232 million, surpassing analysts’ estimate.

TRVN shares have slipped 23% in the trailing 52 weeks. Meanwhile, it has gained 16% since the beginning of this year.

Trevena announced that it has identified a new candidate for its S1P receptor program, designated as TRV045, which holds promise as a new mechanism for non-opioid treatment of chronic pain and other central nervous system disorders.

CEO Carrie Bourdow said, “We have achieved meaningful milestones with our early-stage pipeline assets and, in 2019, expect to continue the development of these assets to build long-term stockholder value.”

On Tuesday, shares of Cara Therapeutics (CARA) surged about 10% during the extended trading hours, after reporting better-than-expected results in the fourth quarter. Viking Therapeutics (VKTX) is scheduled to report quarterly results after the closing bell today.

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Walmart (WMT) stock research summary | Q3 2021

Walmart (WMT) is a major retailer with a strong presence in the US and international markets. The company offers a wide range of products through its stores and digital channels.

MDB Stock: Is it the right time to invest in MongoDB?

The ongoing information technology boom has spurred the need for effective tools for database management, and enterprises are turning to technology companies like MongoDB Inc. (NASDAQ: MDB) to integrate their

After strong Q3, Thermo Fisher (TMO) expects to end FY21 on a high note

The shares of Thermo Fisher Scientific Inc. (NYSE: TMO), a leading provider of analytical instruments and software, climbed to a record high this week, extending the positive momentum that came

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top